A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #862

Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis.

Greenblatt ZL, Tork A, Cruz I, et al. Metabolism open. 2026.
MixedMeta-analysisMentions: Semaglutide

Editor's note

The first meta-analysis of GLP-1 receptor agonists' direct mitochondrial effects in human-derived cell models reports improved bioenergetics and reduced mitochondrial reactive oxygen species, with no clear effect on membrane potential. The authors are candid that overall certainty is very low, driven by heterogeneity, imprecision, and publication bias, and that relevance to whole-body physiology is unproven. Semaglutide appears as a class exemplar rather than the sole agent, so read this as an early mechanistic hint, not established benefit.

Plain-language abstract

Pooling 11 lab-dish studies, researchers found GLP-1 drugs like semaglutide may improve cell energy production and lower harmful oxidative byproducts, but the authors rate the overall evidence as very low certainty.